Profil bibliographique

Julie Rae

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

47Publications signalées

3683Citations signalées

1Affiliations récentes

Institutions déclarées

Kaiser Permanente San Francisco Medical Center

Domaines associés

Neutrophil, Myeloperoxidase and Oxidative MechanismsImmune cells in cancerImmune Response and InflammationChronic Lymphocytic Leukemia ResearchImmunodeficiency and Autoimmune Disorders

Publications récentes

2025 articleOpenAlex

L’obinutuzumab prometteur dans la néphrite lupique indépendamment des biomarqueurs sérologiques initiaux : analyse exploratoire post hoc de l’étude de phase II NOBILITY

S. Jousse Joulin, Edward M Vital, Bernardo Vargas‐Leitón, Julie Rae et autres

0 citationsRevue du Rhumatisme

Accès ouvert 2025 conference-abstractOpenAlex

POS0966 OBINUTUZUMAB SHOWS PROMISE IN LUPUS NEPHRITIS REGARDLESS OF BASELINE SEROLOGICAL BIOMARKERS: AN EXPLORATORY POST HOC ANALYSIS OF THE PHASE II NOBILITY STUDY

Edward M Vital, Bernardo Vargas‐Leitón, Julie Rae, Tao Wang et autres

0 citationsAnnals of the Rheumatic Diseases

Accès ouvert 2023 articleOpenAlex

Disrupted identities, invisibility and precarious support: a mixed methods study of LGBTQI adolescents and young adults with cancer

Jane M. Ussher, Kimberley R. Allison, Rosalie Power, Samantha Ryan et autres

21 citationsBMC Public Health

Accès ouvert 2023 articleOpenAlex

Supporting Lgbtqi Communities Impacted By Breast Cancer: Results And Translational Outcomes Of The Out With Cancer Study

Julie Rae, Jane M. Ussher, Janette Perz, Kimberley R. Allison et autres

0 citationsThe Breast

Accès ouvert 2021 articleOpenAlex

Identification of an IL-22-Dependent Gene Signature as a Pharmacodynamic Biomarker

Julie Rae, Jason A. Hackney, Kevin Huang, Mary Keir et autres

3 citationsInternational Journal of Molecular Sciences

Accès ouvert 2021 articleOpenAlex

Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC‐0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

David Isenberg, Richard Furie, Nicholas S. Jones, Pascal Guibord et autres

140 citationsArthritis & Rheumatology

Accès ouvert 2020 conference-abstractOpenAlex

OP0233 EFFICACY, SAFETY, AND PHARMACODYNAMIC EFFECTS OF THE BRUTON'S TYROSINE KINASE INHIBITOR, FENEBRUTINIB (GDC-0853), IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS IN A PHASE 2 CONTROLLED STUDY

David Isenberg, Richard Furie, Nicholas S. Jones, Pascal Guibord et autres

19 citationsAnnals of the Rheumatic Diseases

Accès ouvert 2020 articleOpenAlex

Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double‐Blind, Phase II Trial

Stanley Cohen, Katie Tuckwell, Tamiko R. Katsumoto, Rui Zhao et autres

122 citationsArthritis & Rheumatology

2019 conference-abstractOpenAlex

FRI0129 THE BTK INHIBITOR, FENEBRUTINIB, EFFECTIVELY MODULATES B AND MYELOID CELL BIOLOGY IN RHEUMATOID ARTHRITIS PATIENTS

Alyssa Morimoto, Julie Rae, Leslie W. Chinn, Nandhini Ramamoorthi et autres

3 citationsAnnals of the Rheumatic Diseases

Accès ouvert 2019 articleOpenAlex

Family-based prevention programmes for alcohol use in young people

Conor Gilligan, Luke Wolfenden, David Foxcroft, Amanda Williams et autres

48 citationsCochrane Database of Systematic Reviews

Accès ouvert 2018 articleOpenAlex

Nonclinical safety assessment of a human interleukin‐22 FC IG fusion protein demonstrates in vitro to in vivo and cross‐species translatability

Donna W. Lee, Shelly Zhong, Rama Pai, Julie Rae et autres

15 citationsPharmacology Research & Perspectives

2018 articleOpenAlex

Pre-clinical and translational pharmacology of a human interleukin-22 IgG fusion protein for potential treatment of infectious or inflammatory diseases

Eric Stefanich, Julie Rae, Siddharth Sukumaran, Jeff Lutman et autres

60 citationsBiochemical Pharmacology

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.